Farallon Capital Management LLC Has $624,000 Stock Holdings in Alkermes plc $ALKS

Farallon Capital Management LLC decreased its holdings in shares of Alkermes plc (NASDAQ:ALKS) by 97.0% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 20,800 shares of the company’s stock after selling 670,863 shares during the period. Farallon Capital Management LLC’s holdings in Alkermes were worth $624,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in ALKS. Commodore Capital LP grew its stake in shares of Alkermes by 26.4% during the third quarter. Commodore Capital LP now owns 3,096,754 shares of the company’s stock worth $92,903,000 after purchasing an additional 646,754 shares during the period. Baker BROS. Advisors LP lifted its stake in Alkermes by 26.2% in the third quarter. Baker BROS. Advisors LP now owns 8,091,351 shares of the company’s stock valued at $242,741,000 after buying an additional 1,680,748 shares during the period. California Public Employees Retirement System lifted its stake in Alkermes by 4.0% in the third quarter. California Public Employees Retirement System now owns 320,879 shares of the company’s stock valued at $9,626,000 after buying an additional 12,337 shares during the period. Algert Global LLC boosted its holdings in Alkermes by 18.0% during the third quarter. Algert Global LLC now owns 135,970 shares of the company’s stock worth $4,079,000 after buying an additional 20,700 shares during the last quarter. Finally, Alliancebernstein L.P. boosted its holdings in Alkermes by 18.0% during the third quarter. Alliancebernstein L.P. now owns 238,539 shares of the company’s stock worth $7,156,000 after buying an additional 36,359 shares during the last quarter. Institutional investors and hedge funds own 95.21% of the company’s stock.

Alkermes Stock Performance

ALKS opened at $27.76 on Monday. Alkermes plc has a 52-week low of $25.17 and a 52-week high of $36.32. The firm has a market capitalization of $4.63 billion, a PE ratio of 19.41, a PEG ratio of 6.92 and a beta of 0.53. The business’s 50-day simple moving average is $31.58 and its 200 day simple moving average is $30.20.

Alkermes (NASDAQ:ALKS) last issued its quarterly earnings results on Wednesday, February 25th. The company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.43 by ($0.14). The company had revenue of $384.55 million for the quarter, compared to analyst estimates of $380.44 million. Alkermes had a net margin of 16.37% and a return on equity of 14.91%. The business’s revenue for the quarter was down 10.6% on a year-over-year basis. During the same period last year, the company posted $1.05 earnings per share. Alkermes has set its FY 2026 guidance at -0.798–0.680 EPS. On average, research analysts forecast that Alkermes plc will post 1.31 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Craig C. Hopkinson sold 9,000 shares of the firm’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $29.72, for a total value of $267,480.00. Following the completion of the transaction, the executive vice president directly owned 89,389 shares of the company’s stock, valued at approximately $2,656,641.08. This trade represents a 9.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP David Joseph Gaffin sold 2,034 shares of the firm’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $29.29, for a total transaction of $59,575.86. Following the completion of the transaction, the executive vice president directly owned 237,660 shares of the company’s stock, valued at $6,961,061.40. This represents a 0.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 157,434 shares of company stock worth $5,305,794. 4.40% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on ALKS. Wells Fargo & Company boosted their target price on Alkermes from $37.00 to $43.00 and gave the stock an “overweight” rating in a research report on Thursday, February 26th. Weiss Ratings reissued a “hold (c+)” rating on shares of Alkermes in a research note on Monday, December 29th. HC Wainwright restated a “neutral” rating and set a $43.00 price objective on shares of Alkermes in a report on Thursday, February 26th. Wolfe Research began coverage on shares of Alkermes in a report on Monday, February 23rd. They issued an “outperform” rating and a $45.00 target price on the stock. Finally, Truist Financial increased their target price on shares of Alkermes from $50.00 to $55.00 and gave the stock a “buy” rating in a report on Monday, November 17th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, Alkermes currently has a consensus rating of “Moderate Buy” and an average target price of $44.07.

Alkermes Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.